Trial Profile
A Randomized, Double-Blind Study of Neural Circuit Responses to COMT Inhibitors in PPG
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 17 Feb 2021
Price :
$35
*
At a glance
- Drugs Tolcapone (Primary)
- Indications Parkinson's disease
- Focus Pharmacodynamics
- 20 May 2016 New trial record